((自动化翻译由路透提供，请见免责声明 ))
1月10日 - ** Intellia Therapeutics 股价盘前下跌4.2%，报11.52美元
** NTLA周四宣布计划停止其治疗一种肺病的早期疗法NTLA-3001的研发
** 公司还计划今年裁员约 27
** 公司计划将资源重新集中于两种后期疗法--NTLA-2002和nex-z--并为它们的商业化上市做准备
** 在公司发布公告后，至少有三家券商下调了对 NTLA 股票的 PT 值
** BMO Capital分析师称，投资者可能会质疑NTLA做出决定的时机，因为NTLA-3001的早期试验将于2024年下半年开始。
** 停产NTLA-3001 "是一个正确的决定，可以减轻NTLA的融资压力"--BMO资本公司
** NTLA表示，截至2024年底，公司拥有约8.62亿美元的现金及等价物；现金余额和预期的成本节约将为2027年上半年提供现金支持
** 2024 年股价下跌约 62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.